hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06346106, orgStudyIdInfo id: 23-0075, briefTitle: The Diagnostic Experience of Male Rett Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-24, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Children's Hospital Colorado, class: OTHER, collaborators name: University of Colorado, Denver, collaborators name: Vanderbilt University School of Medicine, collaborators name: University of Alabama at Birmingham, collaborators name: University of Pennsylvania, collaborators name: International Rett Syndrome Foundation, collaborators name: Rocky Mountain Rett Association, descriptionModule briefSummary: The Diagnostic Experience of Male Rett Syndrome collects information on the lived experiences of parents or caregivers to boys with Rett Syndrome. Key information examined includes the process of getting a male Rett syndrome diagnosis, your son's systems of care, and your priorities for his health needs.Enrolled participants will complete an online survey with questions about having a son with Rett Syndrome. The Diagnostic Experience of Male Rett Syndrome study is available to parents or caregivers to boys (alive or passed) with Rett Syndrome. Compensation is not provided., conditionsModule conditions: Rett Syndrome, conditions: RTT, designModule studyType: OBSERVATIONAL, designInfo observationalModel: FAMILY_BASED, timePerspective: RETROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Male Rett, outcomesModule primaryOutcomes measure: Diagnostic experiences, primaryOutcomes measure: Attainment of developmental milestones and any regressions, primaryOutcomes measure: QI-disability, primaryOutcomes measure: Parent priorities for care and counseling, primaryOutcomes measure: Parenting experience, primaryOutcomes measure: Information regarding child's death, if applicable, secondaryOutcomes measure: Family demographics, secondaryOutcomes measure: Systems of supports, secondaryOutcomes measure: Healthcare preferences, eligibilityModule sex: MALE, minimumAge: 0 Years, maximumAge: 100 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Colorado Anschutz Medical Campus, status: RECRUITING, city: Aurora, state: Colorado, zip: 80045, country: United States, contacts name: Natalia Klamut, role: CONTACT, phone: 720-277-9095, email: malerettstudy@cuanschutz.edu, contacts name: Timothy Benke, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Talia Thompson, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 39.72943, lon: -104.83192, hasResults: False
protocolSection identificationModule nctId: NCT06346093, orgStudyIdInfo id: CHEC2024-089, briefTitle: Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Xiangyu Kong, class: OTHER, descriptionModule briefSummary: This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD-L1 therapy in the advanced gastric cancer., conditionsModule conditions: Advanced Gastric Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: Fecal Microbiota Transplantation Capsules, interventions name: Placebo, outcomesModule primaryOutcomes measure: Objective response rate (ORR), primaryOutcomes measure: Rate of Disease Control, secondaryOutcomes measure: Progression-free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Incidence of Adverse Events Related to Treatment, secondaryOutcomes measure: Change in the intestinal microbiome community, secondaryOutcomes measure: Quality of life based on the questionnaire, secondaryOutcomes measure: Quality of life based on the questionnaire, secondaryOutcomes measure: Change in the immunity, otherOutcomes measure: Marker of nutritional status, otherOutcomes measure: Marker of nutritional status, otherOutcomes measure: Marker of nutritional status, otherOutcomes measure: Body Weight, otherOutcomes measure: Appetite, otherOutcomes measure: Marker of nutritional status, otherOutcomes measure: Marker of nutritional status, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Changhai Hospital, city: Shanghai, state: Shanghai, zip: 200433, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06346080, orgStudyIdInfo id: s68670, briefTitle: Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment, acronym: MAGECmultiDiCE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2026-08-01, completionDateStruct date: 2026-08-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: KU Leuven, class: OTHER, descriptionModule briefSummary: The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.The main question it aims to answer are:* Which diagnostic modality is preferred by patients and the general population?* Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality?* Are geographical differences present in regard to the preference for a diagnostic modality?Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors., conditionsModule conditions: Esophageal Cancer, conditions: Gastric Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: A survey will be conducted in a single group of participants from different geographical regions and backgrounds, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 2200, type: ESTIMATED, armsInterventionsModule interventions name: Survey, outcomesModule primaryOutcomes measure: The rate of contribution of diagnostic features to the preference of participants, primaryOutcomes measure: The percentage differences in preference of participants between geographical regions, secondaryOutcomes measure: Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio, secondaryOutcomes measure: Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06346054, orgStudyIdInfo id: s68669, briefTitle: Molecular Assessment for Gastro-Esophageal Cancer, acronym: MAGEC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2029-07-01, completionDateStruct date: 2029-07-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: KU Leuven, class: OTHER, descriptionModule briefSummary: The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.The main questions this study aims to answer:Are oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.Participants will provide a breath and blood sample during their routine standard of care visits., conditionsModule conditions: Esophageal Cancer, conditions: Gastric Cancer, conditions: Barrett Esophagus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants with gastro-esophageal cancer, participants with Barrett's esophagus and Healthy controls will be monitored in parallel to identify oncometabolic biomarkers related to cancer, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Breath analysis, interventions name: Blood analysis, outcomesModule primaryOutcomes measure: Identification of the concentrations of oncometabolites, secondaryOutcomes measure: Assessment of incidence of early-stage cancer, secondaryOutcomes measure: Assessment of incidence of therapy response, secondaryOutcomes measure: Assessment of percentage change of therapy response, secondaryOutcomes measure: Assessment of incidence of recurrence, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06346041, orgStudyIdInfo id: HJG-IDOV-SAFE-LYSW, briefTitle: Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, class: OTHER, descriptionModule briefSummary: This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-SAFETM in patients with advanced solid tumors., conditionsModule conditions: Neoplasms, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 19, type: ESTIMATED, armsInterventionsModule interventions name: Oncolytic Virus injection(IDOV-SAFETM), outcomesModule primaryOutcomes measure: Dose Limiting Toxicities (DLT), primaryOutcomes measure: Incidence of adverse events and severe adverse events, primaryOutcomes measure: MTD/MFD, secondaryOutcomes measure: The Pharmacokinetics characteristics of IDOV-SAFETM((biological distribution and viral expulsion)), secondaryOutcomes measure: Immunogenicity of IDOV-SAFETM, secondaryOutcomes measure: ORR, secondaryOutcomes measure: DCR, secondaryOutcomes measure: DOR, secondaryOutcomes measure: PFS, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06346015, orgStudyIdInfo id: HX-A-2023050, briefTitle: Gamma Entrainment Stimulation for Cognitive Dysfunction After aSAH, acronym: GES-aSAH, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Beijing Tiantan Hospital, class: OTHER, collaborators name: Shanghai Joyingmed Sensory Stimulation Lab, descriptionModule briefSummary: The goal of this clinical trial is to Explore and verify whether 40Hz audio and binaural beat 40Hz audio can improve the postoperative cognitive dysfunction seen in patients with aneurysmal subarachnoid hemorrhage. This study is a single-center, prospective, randomized, controlled clinical trial. Patients with aneurysmal subarachnoid hemorrhage were selected and randomized into intervention group (audio adjuvant group) and control group (conventional treatment group). Patients in the intervention group will receive audio therapy after surgery, and patients in the control group will receive usual care. EEG, fMRI and mRS scores were evaluated after 3 months of follow-up., conditionsModule conditions: Subarachnoid Hemorrhage, Aneurysmal, conditions: Cognitive Dysfunction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: The relevant neuroimaging evaluation process is blinded to the evaluator to ensure the objectivity of the evaluation results., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Gamma Entrainment Stimulation, outcomesModule primaryOutcomes measure: Montreal Cognitive Assessment (MoCA) scores < 22, primaryOutcomes measure: mini-mental state examiniation (MMSE) < 27, primaryOutcomes measure: modified Rankin Scales (mRS) > 2, secondaryOutcomes measure: electroencephalogram (EEG) indicators, secondaryOutcomes measure: functional Magnetic Resonance Imaging (fMRI) indicators, otherOutcomes measure: Safety indicator, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06346002, orgStudyIdInfo id: 2026_e_2017, briefTitle: Impact of a Mindfulness-based Intervention on Well-being and Mental Health of Elementary School Children, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-03-01, primaryCompletionDateStruct date: 2020-03-31, completionDateStruct date: 2020-03-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Bishop's University, class: OTHER, descriptionModule briefSummary: Background: Prevention programs for children such as mindfulness-based interventions (MBIs) are often implemented in schools to prevent psychological disorders from emerging and contribute to children' mental health.Aim: This study used a randomized cluster design and assessed the impact of a MBI on well-being and mental health of elementary school children's.Method: 13 elementary school classrooms were randomly allocated to the experimental condition (7 classrooms, n = 127 students) or the waitlist control condition (6 classrooms, n = 104 students). Participants in the experimental condition received a 10-week MBI., conditionsModule conditions: Mindfulness-based Intervention, conditions: Elementary School Children, conditions: Mental Health Wellness 1, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized cluster trial with a wait-list control, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 231, type: ACTUAL, armsInterventionsModule interventions name: Mindfulness-based intervention, outcomesModule primaryOutcomes measure: Symptoms of Mental Health Disorders, primaryOutcomes measure: Basic Psychological Needs Satisfaction, primaryOutcomes measure: Process Measure, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: École primaire Préville, city: Saint-Lambert, state: Quebec, zip: J4S 1M8, country: Canada, geoPoint lat: 45.50008, lon: -73.51028, hasResults: False
protocolSection identificationModule nctId: NCT06345976, orgStudyIdInfo id: RLX_2023_10, briefTitle: Functional Impairment in Albinism, acronym: PLAIB, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Fondation Ophtalmologique Adolphe de Rothschild, class: NETWORK, descriptionModule briefSummary: Albinism is a genetic and hereditary anomaly that affects pigmentation. This pathology is characterized by a deficit in melanin production. In humans, the clinical diagnosis of albinism is based on a number of factors, including :* In the integumentary region: fair skin tone, with white hair, eyelashes and eyebrows.* Ophthalmological: reduced visual acuity, photophobia, nystagmus, transilluminated blue irises, hypopigmentation of the retina at the back of the eye with fovea plana.As treatment options begin to emerge for certain albinism-induced anomalies (including, for example, the depigmentation that causes photophobia), it is desirable to understand what these patients' complaints are, and to gather their views on the emergence of treatments targeting just one of their complaints, namely glare., conditionsModule conditions: Albinism, Ocular, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: questionnaire, outcomesModule primaryOutcomes measure: To determine whether patients with albinism would be interested in a treatment that could improve their glare without improving their visual acuity., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06345963, orgStudyIdInfo id: HSC-MS-23-1044, briefTitle: Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2029-05-01, completionDateStruct date: 2030-05-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: The University of Texas Health Science Center, Houston, class: OTHER, descriptionModule briefSummary: Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity., conditionsModule conditions: Schizophrenia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: active H-coil delivered rTMS, outcomesModule primaryOutcomes measure: brain microstructural integrity from magnetic resonance imaging (MRI), primaryOutcomes measure: Resting-state functional connectivity (rsFC) from functional MRI, secondaryOutcomes measure: Electrophysiological responses measured by mismatch negativity and steady-state auditory evoked potentials from electroencephalography recording (EEG), secondaryOutcomes measure: Cognitive insight, depression, perception, and delusion measured from questionnaires, secondaryOutcomes measure: Cognitive functions measured by the MATRICS consensus cognitive battery (MCCB), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: The University of Texas Health Science Center, Houston, city: Houston, state: Texas, zip: 77054, country: United States, contacts name: Xiaoming Du, PhD, role: CONTACT, phone: 410-402-6036, email: Xiaoming.Du@uth.tmc.edu, contacts name: Victoria Acosta, role: CONTACT, phone: 713-486-2740, email: Victoria.Acosta@uth.tmc.edu, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06345924, orgStudyIdInfo id: Meraki_Palliative Care, briefTitle: Music Therapy for Cancer Patients(Meraki_PC), acronym: Meraki_Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of Valencia, class: OTHER, descriptionModule briefSummary: The overall aim of the study is to analyse the impact of a music therapy-based treatment on the emotional well-being and quality of life of cancer patients in palliative care (PC). To this end, the effectiveness and efficiency of a music therapy-based treatment to improve adaptation to illness and psychological well-being in this population will be validated and implemented.Specifically, the implementation of an individualised treatment programme for palliative care patients will be carried out., conditionsModule conditions: Cancer, conditions: Palliative Care, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: MERAKI_PC, outcomesModule primaryOutcomes measure: Change in Anxiety and Depression Symptomatology (T1, T2 and T4), primaryOutcomes measure: Change in Quality of Life (T1, T2 and T4), primaryOutcomes measure: Change in emotional distress (T1, T2, T3 and T4), secondaryOutcomes measure: Change in Social Suport (T1 and T4), secondaryOutcomes measure: Change in Resilience (T1 and T4), secondaryOutcomes measure: Change in Spirituality (T1 and T4), secondaryOutcomes measure: Change Knowledge of the disease (T1 and T4), secondaryOutcomes measure: Barthel Index, secondaryOutcomes measure: Pfeiffer Short Form Mental State Questionnaire, SPMSQ, secondaryOutcomes measure: Charlson Comorbidity Index (CCI), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Dr. Moliner, status: RECRUITING, city: Serra, state: Valencia, country: Spain, contacts name: Miguel Fombuena, PhD, role: CONTACT, email: fombuena_mig@gva.es, contacts name: Selene Valero-Moreno, PhD, role: SUB_INVESTIGATOR, contacts name: Isabel Bellver Vercher, role: SUB_INVESTIGATOR, contacts name: Ana Alegre Soler, role: SUB_INVESTIGATOR, contacts name: José Jorge Botella Trellis, Dr., role: SUB_INVESTIGATOR, contacts name: Cristina Rocío Espejo Fernández, Dra., role: SUB_INVESTIGATOR, contacts name: María Carmen Badía Picazo, Dra., role: SUB_INVESTIGATOR, geoPoint lat: 39.68333, lon: -0.43333, hasResults: False